Please ensure Javascript is enabled for purposes of website accessibility

GW Pharmaceuticals Just Unlocked a Significant Growth Opportunity

By David Jagielski - Oct 2, 2019 at 7:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Approval in Europe for its cannabidiol-based drug will give the company another lucrative market to tap into.

Investors looking to capitalize on the growing popularity of medical marijuana may want to consider buying shares of GW Pharmaceuticals (GWPH). While the company may not want to refer to itself as a cannabis stock, it's definitely benefiting from the soaring sales growth of its drug Epidiolex. The first (and so far, only) drug derived from cannabidiol (CBD) that's been approved by the U.S. Food and Drug Administration, Epidiolex has helped put the company on the map.

The stock was up more than 90% this year before a big market correction sent many cannabis and cannabis-related stocks plummeting over the past several months, as investors opted for less risky investments. However, GW Pharmaceuticals is not nearly as risky as other marijuana stocks, and it could be poised for significant growth.

Last month, the company found out Epidiolex would be approved in Europe as a treatment option for certain forms of epilepsy.

Epidiolex can be sold to 28 more countries

The approval opened not a door, but a floodgate, to even more growth for the company. GW has just been scratching the surface in the U.S. market, and now it has the ability to grow in Europe as well. The company isn't wasting any time; GW Pharmaceuticals CEO Justin Gover spoke with Jim Cramer: "We'll be launching these countries over the next year or two." GW is even hoping for products to start being sold in multiple European countries before the year is over.

Europe at night, seen from space

IMAGE SOURCE: GETTY IMAGES.

The medical marijuana market is a great growth opportunity in Europe, where it's still fairly small. According to data collected by Rolling Stone, the CBD market in Europe is expected to reach $1.7 billion in 2023, which is more than quadruple the estimate for 2019 -- $416 million.

With the European market still in its early growth stages, it's an optimal time for GW to establish a leadership position. The more success that Epidiolex has in both the U.S. and European markets, the better its chances for further growth, as patients and doctors are convinced of its effectiveness.

Why investors should be excited

Even before the news of GW receiving European approval, the stock was looking very promising. In the company's most recent quarterly earnings report, sales reached $71 million, up from just $3 million in the prior year. With Europe now in the mix, those numbers could get a whole lot bigger a whole lot faster. And while there's negative press surrounding vaping and the recreational market, GW presents a much safer option for investors, because it's not exposed to those risks.

With GW's stock price dropping 35% over the last three months, investors have the ability to buy in at prices that were last seen in January -- before the impressive quarterly results and before news of the European approval. While the stock is trading at a premium of 25 times sales today, it could be well worth it, given the massive opportunities that the company now has on two continents.

David Jagielski has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc
GWPH

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
390%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.